*To the Editor*:

L[eung]{.smallcaps} *et al.* \[[@C1]\] have recently published, in the *European Respiratory Journal*, a paper on the expression of angiotensin-converting enzyme II (ACE-2) in the small airway epithelia of smokers and COPD patients, discussing its effects on the risk of severe coronavirus disease 2019 (COVID-19). The authors found an increased expression of the ACE-2 gene in the airways of subjects with COPD and in current smokers. Indeed, a recent systematic review reporting data on the smoking habits of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), concluded that smoking may be associated with a negative progression of the disease and with the adverse outcome \[[@C2]\]. These conclusions were challenged in a correspondence by C[ai]{.smallcaps} \[[@C3]\] on the basis that a reliable mechanism explaining this association was missing. The need for these results to be supported by additional studies is quite clear, but we believe that a robust mechanistic explanation exists. Nicotine has a known influence on the homeostasis of the renin--angiotensin system (RAS) up-regulating the angiotensin-converting enzyme (ACE)/angiotensin (ANG)-II/ANG II type 1 receptor axis, and down-regulating the compensatory ACE-2/ANG-(1--7)/Mas receptor axis, contributing in turn to the development of cardiovascular and pulmonary diseases \[[@C4]\]. Different airway cells, such as bronchial epithelial cells, type II alveolar epithelial cells and interstitial lung fibroblasts, express nicotinic acetylcholine receptors (nAChR), specifically the α7subtype \[[@C5]\]. All these cells express components of the RAS \[[@C4]\]. In addition, nicotine increases the expression and/or activity of ACE in the lung \[[@C4]\], an increase which has been found also in the serum of smokers, and that required at least 20 min to return to control level \[[@C4]\]. ACE-2 serves as a physiologically relevant cellular entry receptor for SARS-CoV, for the human respiratory coronavirus NL63, and probably for SARS-CoV-2 \[[@C6]\]. ACE binds the SARS-CoV-2 S protein, and through its tissutal expression mediates the localisation and the efficiency of the infection \[[@C6]\]. Moreover, nicotine induces the epithelial--mesenchymal transition (EMT) \[[@C5], [@C7]\], a mechanism sufficient to allow "normal" differentiated cells to acquire the stem cell-like characteristics and properties. We planned experiments on human bronchial epithelial cells (HBEpC), obtained from Cell Applications Inc. ([www.cellapplications.com/product](www.cellapplications.com/product) number 502K-05a). Cells were maintained as adherent monolayer in complete bronchial/tracheal epithelial cell growth medium ([www.cellapplications.com/product](www.cellapplications.com/product)) at 37°C in 95% air/5% CO~2~, seeded at an initial density of 7.5×10^4^ cells·cm^−2^, and sub-cultured with a 0.25% trypsin--1 mM EDTA solution (Sigma-Aldrich, Milan, Italy) when cultures reached 80% confluence. HBEpC are derived from the surface epithelium of normal human bronchi non-diseased (*i.e.* asthma, COPD or type 2 diabetes). The morphology is consistent with epithelial origin, and is positive for epithelial cell marker cytokeratin 18. Semi-confluent HBEpC at fourth passage (7.5×10^4^ cells·cm^−2^) were treated: 1) for 1 h with zero or 1.0×10^−7^ M nicotine (Sigma-Aldrich, Milan, Italy) dissolved in saline in complete medium; 2) with 1.0×10^−6^ M α-Bungarotoxin (α-BTX; Sigma-Aldrich, Milan, Italy) dissolved in saline, in the continued presence of nicotine at zero or 1.0×10^−7^ M for 1 h; 3) treated continuously with nicotine for additional passages, 1 passage every 48 h for a total of 16 passages. We showed, for the first time, that nicotine at 1×10^−7^ M (the concentration present on the alveolar lining fluids after one cigarette is in the range 6×10^−6^ to 6×10^−5^ M \[[@C5]\]) is able to increase ACE-2 ([figure 1a](#F1){ref-type="fig"}) in HBEpC. Treatment with nicotine induces phospho-S6 ribosomal protein (Ser235/236), Akt1, phospho-Akt (Ser473), phospho-Akt (Thr308) and phospho-p44/42 MAPK (Thr202/Tyr204) ([figure 1b](#F1){ref-type="fig"}). To verify the hypothesis that ACE-2 is induced by nicotine through α7-nAChR, HBEpC, at fourth passage, in the exponential growth phase, plated at a density of 1×10^6^ cells·mL^−1^, were incubated with α7-nAChR siRNA (0.1 μg) diluted in 100 μL of siRNA transfection medium. Transfection was performed as described by L[i]{.smallcaps} *et al.* \[[@C8]\], who transfected, successfully, HBE16 human airway epithelial cell line (unaffected cells). A clone of transfected HBEpC that did not express α7-nAChR proteins, also after treatment with nicotine ([figure 1c](#F1){ref-type="fig"}), and is not able to induce phospho-S6 ribosomal protein (Ser235/236), Akt1, phospho-Akt (Ser473), phospho-Akt (Thr308) and phospho-p44/42 MAPK (Thr202/Tyr204) after nicotine treatment ([figure 1d](#F1){ref-type="fig"}), was selected for further experiments. Nicotine did not induce ACE-2 in this clone (si-mRNA-α7-HBEpC) ([figure 1a](#F1){ref-type="fig"}). This observation supports the hypothesis that ACE-2 increase is specifically mediated by α7-nAChR. Moreover, when HBEpC were incubated simultaneously with nicotine and α-BTX, an α7 nicotine antagonist \[[@C9]\], no induction of ACE-2 was observed ([figure 1d](#F1){ref-type="fig"}). Importantly, treatment with nicotine, α-BTX or with the combination is not cytotoxic (data not shown). On these bases, we suggest that smoking may promote cellular uptake mechanisms of SARS-CoV-2 through α7-nAChR signalling. A possible α7-nAChR down-stream mechanism may be the induction of phospho-Akt and phospho-p44/42 MAPK. This mechanism was hypothesised, partially, by O[lds]{.smallcaps} and K[abbani]{.smallcaps} \[[@C10]\] on their schematic model explaining how nicotine exposure increases the risk of SARS-CoV-2 entry into lung cells. α7-nAChR is present both in neuronal and non-neuronal cells (*i.e.* lung, endothelial, lymphocyte); consequently, smoking may impact COVID-19 pathophysiology and clinical outcome in several organ systems, including the brain.

![Effect of nicotine on human bronchial epithelial cells (HBEpC) or si-mRNA-α7-HBEpC. a) Angiotensin-converting enzyme II (ACE-2) detection. ACE-2 was measured with human ACE-2 ELISA kit ab235649 ([www.abcam.com/human-ace2-elisa-kit-ab235649.html](www.abcam.com/human-ace2-elisa-kit-ab235649.html)) according to the manufacturer\'s instructions. Data are mean±[sem]{.smallcaps}; p-vaule was evaluated using t-test. The green plots are the human ACE-2 standard. Experiments were performed twice in triplicate. b) Induction of phospho-S6 ribosomal protein (Ser235/236), Akt1, phospho-Akt (Ser473), phospho-Akt (Thr308) and phospho-p44/42 MAPK (Thr202/Tyr204) in HBEpC. Data were obtained using PathScan® cell growth Multi-target Sandwich ELISA kit n.7239 (Cell Signaling) PathScan® Cell Growth Multi-Target Sandwich ELISA Kit is a solid phase sandwich ELISA that combines the reagents necessary to detect endogenous levels of S6 ribosomal protein, phospho-S6 ribosomal protein (Ser235/236), Akt1, phospho-Akt (Ser473), phospho-Akt (Thr308) and phospho-p44/42 MAPK (Thr202/Tyr204). Data are mean±[sem]{.smallcaps}; p-value was evaluated using t-test. Experiments were performed twice in duplicate. c) α7-nAChR protein detection. Western blotting was performed as described previously \[[@C11]\]. Human α7-nAchR antibody NBP1-49348 was purchased from Novus Biologicals ([www.novusbio.com](www.novusbio.com)). 1--2 si-mRNA-α7-HBEpC treated with zero (lane 1) or 1.0×10^−7^ M nicotine (lane 2) for 1 h. 3--4 HBEpC treated with zero (lane 3) or 1.0×10^−7^ M nicotine (lane 4) for 1 h. Experiments were performed twice. d) as in panel b, but treated cells are si-mRNA-α7-HBEpC.](ERJ-01116-2020.01){#F1}
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